|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DLX2 |
Gene summary for DLX2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DLX2 | Gene ID | 1746 |
| Gene name | distal-less homeobox 2 | |
| Gene Alias | TES-1 | |
| Cytomap | 2q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q07687 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1746 | DLX2 | LZE4T | Human | Esophagus | ESCC | 1.70e-03 | 1.91e-01 | 0.0811 |
| 1746 | DLX2 | LZE21T | Human | Esophagus | ESCC | 1.37e-06 | 2.98e-01 | 0.0655 |
| 1746 | DLX2 | P2T-E | Human | Esophagus | ESCC | 5.57e-40 | 7.90e-01 | 0.1177 |
| 1746 | DLX2 | P4T-E | Human | Esophagus | ESCC | 3.85e-16 | 3.56e-01 | 0.1323 |
| 1746 | DLX2 | P5T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.54e-01 | 0.1327 |
| 1746 | DLX2 | P8T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.00e-01 | 0.0889 |
| 1746 | DLX2 | P9T-E | Human | Esophagus | ESCC | 9.50e-13 | 4.17e-01 | 0.1131 |
| 1746 | DLX2 | P10T-E | Human | Esophagus | ESCC | 4.41e-07 | 2.13e-01 | 0.116 |
| 1746 | DLX2 | P11T-E | Human | Esophagus | ESCC | 2.64e-31 | 1.46e+00 | 0.1426 |
| 1746 | DLX2 | P12T-E | Human | Esophagus | ESCC | 1.31e-36 | 9.29e-01 | 0.1122 |
| 1746 | DLX2 | P15T-E | Human | Esophagus | ESCC | 5.63e-18 | 3.89e-01 | 0.1149 |
| 1746 | DLX2 | P16T-E | Human | Esophagus | ESCC | 1.02e-31 | 6.13e-01 | 0.1153 |
| 1746 | DLX2 | P20T-E | Human | Esophagus | ESCC | 2.32e-06 | 2.13e-01 | 0.1124 |
| 1746 | DLX2 | P21T-E | Human | Esophagus | ESCC | 2.05e-07 | 2.10e-01 | 0.1617 |
| 1746 | DLX2 | P22T-E | Human | Esophagus | ESCC | 1.97e-10 | 2.24e-01 | 0.1236 |
| 1746 | DLX2 | P26T-E | Human | Esophagus | ESCC | 1.30e-15 | 3.06e-01 | 0.1276 |
| 1746 | DLX2 | P27T-E | Human | Esophagus | ESCC | 2.03e-09 | 2.58e-01 | 0.1055 |
| 1746 | DLX2 | P28T-E | Human | Esophagus | ESCC | 8.08e-19 | 4.73e-01 | 0.1149 |
| 1746 | DLX2 | P31T-E | Human | Esophagus | ESCC | 3.52e-19 | 4.38e-01 | 0.1251 |
| 1746 | DLX2 | P32T-E | Human | Esophagus | ESCC | 3.97e-04 | 1.33e-01 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00072197 | Esophagus | ESCC | Notch signaling pathway | 106/8552 | 172/18723 | 1.74e-05 | 1.55e-04 | 106 |
| GO:00420636 | Esophagus | ESCC | gliogenesis | 172/8552 | 301/18723 | 3.75e-05 | 3.04e-04 | 172 |
| GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
| GO:0045746 | Esophagus | ESCC | negative regulation of Notch signaling pathway | 28/8552 | 36/18723 | 8.62e-05 | 6.22e-04 | 28 |
| GO:00100016 | Esophagus | ESCC | glial cell differentiation | 129/8552 | 225/18723 | 2.73e-04 | 1.65e-03 | 129 |
| GO:00519606 | Esophagus | ESCC | regulation of nervous system development | 237/8552 | 443/18723 | 5.02e-04 | 2.78e-03 | 237 |
| GO:00485687 | Esophagus | ESCC | embryonic organ development | 228/8552 | 427/18723 | 7.28e-04 | 3.79e-03 | 228 |
| GO:00085935 | Esophagus | ESCC | regulation of Notch signaling pathway | 59/8552 | 95/18723 | 9.12e-04 | 4.65e-03 | 59 |
| GO:00487052 | Esophagus | ESCC | skeletal system morphogenesis | 120/8552 | 220/18723 | 4.90e-03 | 1.89e-02 | 120 |
| GO:00215436 | Esophagus | ESCC | pallium development | 94/8552 | 169/18723 | 5.79e-03 | 2.14e-02 | 94 |
| GO:19048881 | Esophagus | ESCC | cranial skeletal system development | 41/8552 | 68/18723 | 1.07e-02 | 3.66e-02 | 41 |
| GO:00017639 | Esophagus | ESCC | morphogenesis of a branching structure | 106/8552 | 196/18723 | 1.08e-02 | 3.66e-02 | 106 |
| GO:00512161 | Esophagus | ESCC | cartilage development | 103/8552 | 190/18723 | 1.08e-02 | 3.67e-02 | 103 |
| GO:00487092 | Esophagus | ESCC | oligodendrocyte differentiation | 55/8552 | 95/18723 | 1.10e-02 | 3.72e-02 | 55 |
| GO:00140131 | Esophagus | ESCC | regulation of gliogenesis | 59/8552 | 103/18723 | 1.17e-02 | 3.91e-02 | 59 |
| GO:00507674 | Liver | HCC | regulation of neurogenesis | 181/7958 | 364/18723 | 3.00e-03 | 1.40e-02 | 181 |
| GO:00420631 | Liver | HCC | gliogenesis | 148/7958 | 301/18723 | 1.10e-02 | 4.07e-02 | 148 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| DLX2 | MSC | Oral cavity | ADJ | DPY19L4,KCNJ8,PLCD1, etc. | 1.48e-01 |  |
| DLX2 | PERI | Oral cavity | Healthy | DPY19L4,KCNJ8,PLCD1, etc. | 1.11e-01 |  |
| DLX2 | MSC | Oral cavity | LP | DPY19L4,KCNJ8,PLCD1, etc. | 3.73e-01 |  |
| DLX2 | MSC | Oral cavity | OSCC | DPY19L4,KCNJ8,PLCD1, etc. | 2.48e-01 |  |
| DLX2 | PERI | Oral cavity | OSCC | DPY19L4,KCNJ8,PLCD1, etc. | 1.50e-01 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DLX2 | SNV | Missense_Mutation | c.41N>T | p.Ser14Leu | p.S14L | Q07687 | protein_coding | deleterious(0) | benign(0.342) | TCGA-C8-A26W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| DLX2 | SNV | Missense_Mutation | c.821N>G | p.Ser274Trp | p.S274W | Q07687 | protein_coding | deleterious(0.01) | possibly_damaging(0.675) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DLX2 | SNV | Missense_Mutation | rs200908537 | c.439N>A | p.Gly147Arg | p.G147R | Q07687 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| DLX2 | SNV | Missense_Mutation | novel | c.818N>T | p.Ala273Val | p.A273V | Q07687 | protein_coding | deleterious(0.01) | benign(0.08) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| DLX2 | SNV | Missense_Mutation | novel | c.290N>C | p.Leu97Pro | p.L97P | Q07687 | protein_coding | tolerated(0.05) | benign(0.118) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| DLX2 | SNV | Missense_Mutation | c.236G>A | p.Gly79Asp | p.G79D | Q07687 | protein_coding | tolerated(0.22) | possibly_damaging(0.763) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DLX2 | SNV | Missense_Mutation | novel | c.676G>A | p.Ala226Thr | p.A226T | Q07687 | protein_coding | tolerated(0.08) | benign(0.093) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| DLX2 | insertion | In_Frame_Ins | novel | c.265_266insATG | p.Ser89delinsTyrAla | p.S89delinsYA | Q07687 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DLX2 | SNV | Missense_Mutation | novel | c.191N>A | p.Ser64Asn | p.S64N | Q07687 | protein_coding | tolerated(0.12) | probably_damaging(0.926) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| DLX2 | SNV | Missense_Mutation | novel | c.847N>C | p.Tyr283His | p.Y283H | Q07687 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |